2022 - Research.com Medicine in Belgium Leader Award
His primary scientific interests are in Internal medicine, Surgery, Gastroenterology, Crohn's disease and Infliximab. His Internal medicine study focuses mostly on Inflammatory bowel disease, Ulcerative colitis, Maintenance therapy, Crohn's Disease Activity Index and Azathioprine. The various areas that Paul Rutgeerts examines in his Surgery study include Adalimumab, Placebo, Adverse effect and Clinical trial.
His Gastroenterology research incorporates themes from Chemotherapy, Certolizumab pegol, Vedolizumab, Colonoscopy and Corticosteroid. Paul Rutgeerts has researched Crohn's disease in several fields, including Prospective cohort study, Severity of illness, Intestinal mucosa and C-reactive protein. His studies deal with areas such as Pharmacokinetics, Predictive value of tests, Gastrointestinal agent, Management of Crohn's disease and Concomitant as well as Infliximab.
Internal medicine, Gastroenterology, Crohn's disease, Immunology and Ulcerative colitis are his primary areas of study. The concepts of his Internal medicine study are interwoven with issues in Placebo and Surgery. His Gastroenterology study integrates concerns from other disciplines, such as Crohn's Disease Activity Index, Colectomy, Adverse effect and Colonoscopy.
His Crohn's disease research includes themes of Adalimumab, Azathioprine and C-reactive protein. His Ulcerative colitis research is multidisciplinary, relying on both Golimumab and Colitis. The study incorporates disciplines such as Gastrointestinal agent and Maintenance therapy in addition to Infliximab.
His main research concerns Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease. His Internal medicine research integrates issues from Placebo and Surgery. His Gastroenterology research incorporates elements of Mucosal healing, Adverse effect, Maintenance therapy, Vedolizumab and C-reactive protein.
His Crohn's disease research includes elements of Clinical trial and Ustekinumab. His Ulcerative colitis study integrates concerns from other disciplines, such as Colonoscopy, Pharmacokinetics, Golimumab and Intestinal mucosa. His study focuses on the intersection of Inflammatory bowel disease and fields such as Immunology with connections in the field of Drug.
His primary areas of study are Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Surgery. His Internal medicine study frequently links to related topics such as Placebo. His studies deal with areas such as Odds ratio, Pharmacokinetics, Maintenance therapy, Confidence interval and Combination therapy as well as Gastroenterology.
He interconnects Colonoscopy, Golimumab and Intestinal mucosa in the investigation of issues within Ulcerative colitis. His Inflammatory bowel disease research is multidisciplinary, relying on both Inflammation, Colitis, Immunology and Biopsy. His Surgery research is multidisciplinary, incorporating perspectives in Crohn's Disease Activity Index and Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Targan;Hanauer Sb;van Deventer Sj;Mayer L.
The New England Journal of Medicine (1997)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)
Infliximab for the treatment of fistulas in patients with Crohn's disease.
D.H. Present;P.J. Rutgeerts;S.R. Targan;S.B. Hanauer.
The New England Journal of Medicine (1999)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Jean Frédéric Colombel;William J. Sandborn;Walter Reinisch;Gerassimos J. Mantzaris.
The New England Journal of Medicine (2010)
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
Jeffrey C. Barrett;Sarah Hansoul;Dan L. Nicolae;Judy H. Cho.
Nature Genetics (2008)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Filip Baert;Maja Noman;Severine Vermeire;Gert Van Assche.
The New England Journal of Medicine (2003)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
Andre Franke;Dermot P B McGovern;Jeffrey C. Barrett;Kai Wang.
Nature Genetics (2010)
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey.
The New England Journal of Medicine (2004)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: